Lumos Pharma Inc (LUMO)

NASDAQ
9.25
-0.21(-2.22%)
  • Volume:
    8,017
  • Bid/Ask:
    9.15/9.30
  • Day's Range:
    9.17 - 9.33

LUMO Overview

Prev. Close
9.46
Day's Range
9.17-9.33
Revenue
120K
Open
9.17
52 wk Range
7.23-36.72
EPS
-2.11
Volume
8,017
Market Cap
77.31M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
62,982
P/E Ratio
-
Beta
1.77
1-Year Change
-35.54%
Shares Outstanding
8,357,391
Next Earnings Date
Nov 16, 2021
What is your sentiment on Lumos Pharma Inc?
or
Market is currently closed. Voting is open during market hours.

Lumos Pharma Inc News

  • Oncology players in the red on Celgene deal
    • BySeeking Alpha-

    A wide range of oncology companies are under modest pressure after deal-hungry Bristol-Myers Squibb (NYSE:BMY) announced its $74B bid for Celgene (NASDAQ:CELG), thereby removing a...

  • Key events next week - healthcare
    • BySeeking Alpha-

    Noteworthy events during the week of November 25 - December 1 for healthcare investors. MONDAY (11/26): FDA action date for Loxo Oncology's (NASDAQ:LOXO) larotrectinib in NTRK...

Lumos Pharma Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellBuyStrong SellStrong SellStrong Sell
SummaryStrong SellNeutralStrong SellStrong SellStrong Sell

Lumos Pharma Inc Company Profile

Lumos Pharma Inc Company Profile

Employees
27

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing and commercialization of products, and therapies for people with rare diseases. The Company's lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.

Read More
  • $NLNK Indoximod + gemcitabine and nab-paclitaxel for Pancreatic cancer. Phase 2 data due anytime now. I bought upside calls $20
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.